Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) might have overtaken Opdivo (nivolumab) in the last quarter to become the top-selling cancer immunotherapy and has the most US approvals, but the Bristol-Myers Squibb (NYSE: BMY) drug is ahead in terms of approved indications in the European Union (EU).
Opdivo extended its lead on Tuesday, when European Commission (EC) approval was announced for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
With this decision, Opdivo becomes the first and only PD-1 therapy to receive an EC approval in the adjuvant setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze